Evidence map›Paper›PMID 41985660›Full record

ArticleContemporary clinical trials2026

A double-blind randomized clinical trial of zonisamide and contingency management for alcohol use disorder treatment (ZARRA) protocol.

Paola Palombo, Alex Schmidt, Nicole Akana, Rachel Ryan, Sean Hovland, B Connor Stark, Nicole Rodin, Naomi Chaytor, Michael McDonell, Ekaterina Burduli and 5 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Paola PalomboElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA; Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil. Electronic address: paola.palombo@wsu.edu.
Alex SchmidtElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA.
Nicole AkanaElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA.
Rachel RyanElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA.
Sean HovlandElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA.
B Connor StarkElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA.
Nicole RodinAnalytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Naomi ChaytorElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA.
Michael McDonellElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA.
Ekaterina BurduliElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA.
Matthew LaytonElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA.
John M RollElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA.
Crystal SmithElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA.
André Constantino MiguelElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA.
Sterling McPhersonElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, USA; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, USA; Department of Community and Behavioral Health, Washington State University, Spokane, WA, USA.

Funding

Zonisamide for the Treatment of Alcohol Use Disorder in the Addiction Neuroclinical Assessment FrameworkR01AA028796 · NIAAA · WASHINGTON STATE UNIVERSITY · PI MCPHERSON, STERLING M · 2020 to 2024
$3.2M
NIAAA NIH HHS R01 AA028796
6 · The paper itself

Abstract

backgroundAlcohol Use Disorder (AUD) has a significant negative impact on health and is associated with high morbidity and mortality rates. Despite the availability of pharmacological treatments, abstinence rates remain low, highlighting the need for novel therapeutic approaches. This study aims to evaluate the efficacy of combining Contingency Management (CM) with Zonisamide in promoting alcohol abstinence and reductions in alcohol use among individuals seeking AUD treatment. Additionally, this study will collect data on the Addiction Neuroclinical Assessment ANA framework to identify potential mediators or moderators of treatment outcomes.

methodsThis is a randomized, double-blind, controlled trial involving individuals diagnosed with AUD seeking treatment. Following a two-week induction period, eligible participants will be randomly assigned in equal proportions to one of two 12-week treatment conditions: CM + Zonisamide (experimental condition) or CM + Placebo (control condition). The primary outcome is biochemically verified alcohol abstinence assessed using repeated urine ethyl glucuronide (EtG) testing across the 12-week randomized treatment phase. Both groups will receive incentives for submitting alcohol samples during the first two weeks (induction phase). From weeks three to six, incentives will be contingent on providing alcohol-negative samples. Finally, from weeks seven to fourteen, incentives will be based on medication adherence. Follow-up assessments will be conducted at one, six- and twelve-months post-treatment.

conclusionsIf effective, this treatment could provide significant advancements in AUD treatment by offering a novel, integrated approach to reduce alcohol use. Furthermore, the findings may contribute to a deeper understanding of how ANA-based responses influence treatment outcomes, facilitating the development of more personalized AUD treatment approaches.

Indexed as

Alcohol AbstinenceAlcoholismBehavior TherapyZonisamideAdultCombined Modality TherapyDouble-Blind MethodFemaleGlucuronatesHumansMaleMiddle AgedMotivationRandomized Controlled Trials as Topicethyl glucuronideGlucuronatesZonisamideAddiction Neuroclinical assessmentAlcohol use disorderContingency managementZonisamide

Identifiers

PMID41985660
PMCPMC13689808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.